US/UK/Canada

Share

Contacts

  • STENOCARE A/S
    Nyholmsvej 4 8930 Randers NØ Danmark
    +45 31 77 00 60
    http://www.stenocare.com

    • Quotes

    “We are closely monitoring the weekly sales across our distribution channels to have products ready for patients at all the Danish pharmacies. We have heard concerns from politicians, that there might be challenges securing supply for Denmark. With our ongoing market monitoring and import of products – we will be able to meet the entire demand from all Danish patients”.
    Rolf Steno, CCO
    Pick a time period -
    Tags ( Active)

    STENOCARE - Deadline Soon for Subscription to New Shares at DKK 0.50 Each

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO STENOCARE A/S (“Stenocare” or the "Company") began on January 07 the subscription period for investors to subscribe for new shares at a discounted price of DKK 0.50 each. This is a time limited offer until January 20, 2025 – however some banks have a shorter deadline with deadline around January 15. Shareholders and new investors interested in this offer should check the deadline with their bank.Stenocare has announced a time limited offer to subscribe for new shares in the Company at a discounted price of DKK 0.50

    STENOCARE A/S announces guarantee commitments in ongoing rights issue

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO STENOCARE A/S (“Stenocare” or the “Company”) announces that the Company has received a legally binding guarantee commitment of 2 mDKK from Exelity AB, securing approximately 9.9 percent of the total issue corresponding to approximately 22.0 percent of the minimum subscription. As stated in the announcement of 18 December 2024, the Company has also received legally binding written pre-subscription commitments and compensation-free guarantees from management and existing shareholders of 1.5 mDKK, corresponding to

    STENOCARE – Deadline soon to subscribe for new shares at DKK 0.50 each

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO STENOCARE A/S (“Stenocare” or the "Company") began on January 07 the subscription period for investors to subscribe for new shares at a discounted price of DKK 0.50 each. This is a time limited offer until January 20, 2025 – however some banks, including Nordnet, have a shorter deadline on Monday January 13. Shareholders and new investors interested in this offer should check the deadline with their bank.Stenocare has announced a time limited offer to subscribe for new shares in the Company at a discounted price of

    STENOCARE A/S: The subscription period in Stenocare’s conditional rights issue begins today for the time limited offer of DKK 0,50 per new share

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. Today, January 7, 2025, the subscription period in STENOCARE A/S’ ("Stenocare" or the "Company") rights issue begins. The last day of the subscription

    STENOCARE’s Innovative ASTRUM 10-10 Product Now Available for Norwegian Patients

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO STENOCARE A/S (“Stenocare”) reaches an important milestone with ASTRUM 10-10, which is now ready for sale to Norwegian patients. The innovative and patented medical cannabis oil product, ASTRUM 10-10, has the potential to improve uptake in the blood and thereby enhance the efficacy of the treatment.Stenocare announced on December 2, 2024, that the new innovative medical cannabis oil product, named Astrum 10-10, has been approved for sale in Norway. At the end of December, the first shipment of this product arrived

    STENOCARE A/S: Conditional Rights Issue of up to 20.2 mDKK

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENO NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. The Board of Directors in STENOCARE A/S (“Stenocare” or the “Company”) has today resolved to increase the share capital of Stenocare with up to a

    Communiqué from extraordinary general meeting in STENOCARE

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENO Extraordinary general meetingOn 18 December 2024 an extraordinary general meeting of shareholders of STENOCARE A/S, CVR no. 39024705, was held at Lund Elmer Sandager Law Firm, Kalvebod Brygge 39 -41, DK-1560 København V with the following agenda: Agenda: 1. Appointment of a chairman of the meeting 2. Election of members of the board of directors 3. Authorisation to the board of directors 4. Amendment of articles of association 5. Any other business Re. 1                   Appointment of a chairman

    STENOCARE Gains Danish Approval for New Medical Cannabis CBD100 oil

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO Stenocare has received approval from the Danish Medicines Agency to start selling a new medical cannabis oil product to Danish patients. The new CBD100 product has a very high concentration of CBD active ingredients (100 mg/ml), and this makes Stenocare the only supplier under the Danish Pilot Programme to offer a CBD100 oil product.Since 2018, Stenocare has been a key supplier of medical cannabis oil products under the Danish Pilot Programme, with several prescription-based products approved for sale by the Danish

    STENOCARE 3.0 Strategy: Management Shares Insights in Exclusive Interview with Proinvestor.com

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO Stenocare has announced its STENOCARE 3.0 strategy, unveiled on November 26, which marks a bold new chapter in its mission to become a leader in the medical cannabis industry. This transformative strategy positions Stenocare as a specialised Trading Company, focused on delivering high-quality, prescription-based medical cannabis products to carefully selected markets. By leveraging innovation and global partnerships, Stenocare aims to create superior value for patients and stakeholders.The management team recently

    STENOCARE – Innovative New ASTRUM Product Officially Approved for Sale in Norway

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO STENOCARE A/S (“Stenocare” or the "Company") is proud to announce the approval of its innovative product, Astrum 10-10, for sale in Norway. This milestone paves the way for more patients to access the benefits of medical cannabis treatment. Astrum 10-10 is expected to become available to patients within the next 30 days.Since 2019, Stenocare has been collaborating with partners to develop and test next-generation medical cannabis oil products, positioning itself as a frontrunner in prescription-based medical

    STENOCARE Celebrates Denmark’s Permanent Legalisation of Medical Cannabis

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO Today, the Danish parliament formally agreed on permanent legalisation of medical cannabis. This is fantastic news for both Danish patients and Stenocare, as it ensures continued access to and the sale of medical cannabis in DenmarkThe Ministry of Interior and Health announced today that the political parties have decided to permanently legalise treatment with medical cannabis in Denmark. When the Danish Pilot Programme expires in December 2025, the Danish Parliament will enact legislation to ensure the permanent

    STENOCARE 3.0: Shifting Strategy to Focus on Trading and exit from Production

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on November 26, 2024. STENOCARE A/S (“Stenocare” or the "Company") is pleased to announce the STENOCARE 3.0 Strategy, which will transform the Company into a leading Trading Company specialising in prescription-based medical cannabis products. Previously, the Company operated in two main areas: trading with approved

    Notice to Extraordinary General Meeting in STENOCARE A/S

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENOThe board of directors hereby convenes the shareholders of STENOCARE A/S to an Extraordinary General Meeting, which will be held: 18 December 2024 at 10.30 AM CET (the doors open at 10.00 AM) at law firm Lund Elmer SandagerKalvebod Brygge 39-411560 Copenhagen With the following agenda: 1. Appointment of a chairman of the meeting 2. Election of members of the board of directors 3. Authorisation to the board of directors 4. Amendment of articles of association 5. Any other business ---o---

    STENOCARE Welcomes Danish Health Minister’s Decision to Permanently Legalise Medical Cannabis for Patients

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO The Danish Pilot Programme for medical cannabis is set to become a permanent legalisation for the treatment of Danish patients, according to the government. Today, the Danish Health Minister invited political parties to discuss the permanent legalisation of medical cannabis in Denmark. This is excellent news for Danish patients and Stenocare, as it secures future access to and sales of medical cannabis in Denmark.In 2018, the Danish Parliament approved a Pilot Programme to allow treatment with medical cannabis

    Interim Report Third Quarter 2024

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENOSTENOCARE A/S (“STENOCARE”) today announces its results for the period 01.01.2024 – 30.09.2024. The report, which has not been reviewed by the Company’s auditors, is attached to this release and is also available on https://stenocare.com/investor-relations/ Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments: ” Stenocare sales is lower than expected even though we have been successful with approval of a new product in Denmark. In Q3 we announced the unique new Astrum value proposition is ready for German

    STENOCARE Change in the Board of Directors

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENOThis information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on November 01, 2024. STENOCARE A/S (“Stenocare” or the “Company”) is changing the Board of Directors. Board member Søren Kjær will leave the board. The Company will nominate Rolf Steno to join the Board at the next general meeting. The Company has accepted the resignation from Board member Søren Kjær and would like to

    STENOCARE updates guidance for 2024

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on October 14, 2024. STENOCARE A/S (“Stenocare” or the “Company”) is updating its guidance from August 20 2024, based on actual market performance in Q3 2024 which has impacted the Company’s 2024 guidance. The guidance of gross sales of between 6-8 mDKK is now expected to be 4.5 mDKK for 2024. The Company is exploring

    Interim Report Second Quarter 2024

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENO STENOCARE A/S (“STENOCARE”) today announces its results for the period 01.01.2024 – 30.06.2024. The report, which has not been reviewed by the Company’s auditors, is attached to this release and is also available on https://stenocare.com/investor-relations/Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments:”Stenocare sales are lower than expected even though we have successfully managed to further improve financial health of the Company and launch new products in several markets, thereby delivering on our

    STENOCARE updates guidance for 2024

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on August 20, 2024. STENOCARE A/S (“Stenocare” or the “Company”) is updating the guidance from November 06, 2023 based on actual market performance from Q1 and Q2 2024 and the forecast for Q3 and Q4 2024. The guidance of gross sales of 12-18 mDKK is now expected to be 6-8 mDKK for 2024, which is a growth of +7% compared

    New innovative Stenocare Astrum 10-10 oil product is ready for sale in Germany

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO STENOCARE A/S (Stenocare) and ADREXpharma are now ready to deliver a new and innovative medical cannabis oil product for German patients, that has the potential to revolutionize the market.Stenocare and ADREXpharma have received approval to sell a new and innovative medical cannabis oil product in Germany, set to be available for patients in the fourth quarter of 2024.   The new product is a THC-CBD 10-10 oil in a 30 ml bottle which has the potential to address a large target group of patients in the German

    STENOCARE A/S: Directed issue, refinancing of debt from a major shareholder and new dates

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENOThis information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on June 28, 2024. The existing debt On 12 January 2024, STENOCARE A/S (“Stenocare” or the “Company”) announced that it had refinanced its total debt of approximately 8.2 mDKK. Through partial repayment, renegotiation, and extension, the debt was reduced to approximately 5.4 mDKK. As of 30 June 2024, the debt stands at

    TO2 Warrant Exercise subscribed to 88.3%

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENOThis information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on 25 June 2024. Outcome of TO2 Warrant Exercise STENOCARE A/S (“Stenocare” or the “Company”) announces the outcome of the exercise of its TO2 warrant (“Warrants”) exercise. The Warrants were issued in connection with the executed unit rights issue in May/June 2023 and conversion of 5 mDKK debt in June 2023. Total number

    STENOCARE: Notice for deadline of subscribing at the discounted price of DKK 3.16 per share

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENO The Stenocare TO2 Warrant subscription will end at the close of business on June 21. To benefit from the discounted share price of DKK 3.16 each, owners of TO2 Warrants must exercise their warrants before the deadline.Stenocare is currently offering a time-limited share issue for owners of TO2 Warrants. Owners can subscribe (ie. purchase) new Stenocare shares at a discounted price of DKK 3.16 each. The deadline for subscription at the discounted price is June 21, 2024, at 17:00 Central European Summer Time. TO2

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media